<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuromuscular manifestations of systemic sclerosis (scleroderma)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuromuscular manifestations of systemic sclerosis (scleroderma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuromuscular manifestations of systemic sclerosis (scleroderma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie J Paik, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Varga, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H53434619"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Muscle involvement in systemic sclerosis (SSc; scleroderma) was previously thought to be relatively uncommon. However, it is increasingly recognized as a major contributor to the morbidity and mortality of the disease. Other neurologic abnormalities that are less common in SSc include central, peripheral, and autonomic neuropathies.</p><p>This topic will provide an overview of the neuromuscular manifestations of SSc. The clinical manifestations, diagnosis, and overview of the management of SSc in adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H3011475336"><span class="h1">MYOPATHY</span></p><p class="headingAnchor" id="H2705430189"><span class="h2">Terminology and epidemiology</span><span class="headingEndMark"> — </span>There are no formal definitions or a universally accepted classification schema of systemic sclerosis (SSc; scleroderma)-associated myopathy. Descriptions of SSc-associated muscle involvement have ranged from muscle weakness and abnormal muscle enzymes to stricter definitions that include abnormal electromyography (EMG) or biopsy-based evidence of inflammation, necrosis, or fibrosis in skeletal muscle. There is also no consensus as to whether an inflammatory myopathy in patients with SSc should be considered a complication of the disease, or as a distinct SSc-myositis overlap [<a href="#rid1">1,2</a>]. In this topic, we will include patients identified as having SSc-myositis overlap within the broader category of SSc-associated myopathy. As discussed below, histologic patterns are used to identify different subsets of myopathy; these include dermatomyositis, polymyositis, fibrosing myopathy, immune-mediated necrotizing myopathy, and nonspecific myositis, as well as neurogenic causes of myopathy  (<a class="graphic graphic_figure graphicRef119673" href="/z/d/graphic/119673.html" rel="external">figure 1</a>). (See <a class="local">'Muscle biopsy'</a> below.)</p><p>Estimates for the prevalence of SSc-associated muscle involvement range from 5 to 96 percent, reflecting the lack of diagnostic consensus criteria [<a href="#rid3">3-6</a>]. Up to 42 percent of myositis patients with overlap connective tissue disease have been reported to have SSc [<a href="#rid7">7,8</a>]. Thus, in addition to clear cases of overlap myositis when patients meet classification criteria for both SSc and myositis, there are also other etiologies for myopathy and/or weakness in SSc such as disuse, malnutrition, or other neurologic diseases. Risk factors for SSc-associated myopathy include diffuse cutaneous SSc subtype, African American race, male sex, and shorter SSc disease duration [<a href="#rid9">9,10</a>]. Much of the progress to understand what myopathy is in SSc has relied on muscle histopathology. (See <a class="local">'Muscle biopsy'</a> below.)</p><p>Survival and outcomes such as disability as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) have also been reported to be poor in patients with SSc myopathy. However, due to the lack of consensus classification criteria as noted above, most such studies have included SSc patients with any evidence of muscle disease such as weakness or elevated creatine kinase (CK) [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H4187695538"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>SSc-associated myopathy is suspected in patients with SSc who present with symmetric proximal muscle weakness, with or without elevated muscle enzymes. Patients with severe myopathy can also present with dysphagia, which is also prominent in patients with SSc uncomplicated by myopathy, perhaps in relationship to autonomic neuropathy. Muscle enzyme abnormalities in the absence of muscle weakness should also raise concern for possible SSc-associated myopathy. Other clinical features of SSc are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p>There have also been reports of prominent neck and upper extremity weakness consistent with a brachio-cervical inflammatory myopathy. While brachio-cervical inflammatory myopathy has been reported in association with other diseases such as myasthenia gravis and rheumatoid arthritis, it has also been reported in those with SSc [<a href="#rid12">12</a>]. Of note, in one long-term follow-up study, patients treated with immunosuppression showed improvement in their upper extremity strength, but neck weakness was found to be particularly resistant to therapy [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2127271767"><span class="h2">Evaluation</span></p><p class="headingAnchor" id="H907891083"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should include an assessment for muscle weakness. Patients with SSc-associated myopathy will typically have proximal muscle weakness only. The physical exam should include evaluation of both proximal (including neck) and distal muscles of arms and legs; symmetric proximal more than distal weakness is suggestive of myopathy. Different patterns of weakness suggest an alternative diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5155.html" rel="external">"Approach to the patient with muscle weakness"</a>.)</p><p>In patients with extensive dermal and articular changes, the clinician should assess whether contractures are contributing to apparent muscle weakness.</p><p class="headingAnchor" id="H3569668223"><span class="h3">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing for suspected myopathy should include serum levels of muscle enzymes, CK, and aldolase.</p><p>Serum CK and aldolase levels may be normal or only slightly elevated in SSc-associated myopathy despite an objective reduction in muscle strength. In the European Scleroderma Trials and Research group (EUSTAR) cohort, the frequency of elevated CK levels were discordant with the presence of muscle weakness; 4.4 percent of patients with limited cutaneous SSc had elevated CK levels while 36 percent had muscle weakness [<a href="#rid14">14</a>]. Similarly, 11.3 percent of patients with diffuse cutaneous SSc had elevated CK levels while 28 percent had muscle weakness.</p><p>In patients with overlap myositis with SSc, anti-PM-Scl, anti-U3-RNP, and anti-Ku antibodies are most prevalent. It is not known what percentage of patients with a known SSc-associated myopathy are positive for any one of these antibodies. However, data from general SSc cohorts found a prevalence of 3 to 6 percent for anti-PM-Scl antibodies, 3 percent for anti-U3-RNP antibodies, and 7 to 9 percent for anti-Ku antibodies [<a href="#rid15">15</a>]. Depending on the laboratory or institution, these tests may be ordered in SSc patients with a myopathy either individually or as a myositis panel.</p><p>The presence of specific autoantibodies in patients with SSc-associated muscle disease permits identification of the clinical phenotype. The presence of some of these autoantibodies can sometimes allow for enhanced screening of particular disease manifestations such as interstitial lung disease or gastrointestinal dysmotility.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-PM-Scl 75/100</strong> – Patients with SSc who are anti-PM-Scl positive are more likely to have limited cutaneous involvement with overlap polymyositis or dermatomyositis [<a href="#rid16">16</a>]. These patients are also reported to have better prognosis in terms of interstitial lung disease and mortality when compared with those who are negative for anti-PM-Scl antibodies [<a href="#rid16">16,17</a>]. In at least one case series, arm abductor weakness was more severe than hip flexor weakness in patients with anti-PM-Scl positivity in contrast to patients without these autoantibodies [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-U3-RNP</strong> – SSc patients who are positive for U3-RNP (fibrillarin) antibodies tend to be African American and have diffuse skin disease with muscle involvement and gastrointestinal dysmotility [<a href="#rid19">19</a>]. In one case series, muscle biopsies of these patients were reported to have minimal inflammation [<a href="#rid19">19</a>]. This is consistent with another report that patients with a fibrosing myopathy tended to be positive for anti-U3-RNP [<a href="#rid20">20</a>]. These patients are also reported to develop severe, fatal isolated pulmonary arterial hypertension [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-Ku</strong> – Patients with SSc who are anti-Ku positive are more likely to have an inflammatory myopathy in overlap with SSc or other autoimmune diseases such as systemic lupus erythematosus (SLE) or Sjögren's syndrome (SS). Muscle biopsies most commonly show necrosis and inflammation [<a href="#rid22">22</a>]. Interstitial lung disease is also more common in patients with an inflammatory myopathy [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other autoantibodies</strong> – Other autoantibodies selective for SSc-associated muscle involvement, including anti-SMN and anti-RuvBL1, have been described, but their availability and clinical utility remain to be established [<a href="#rid24">24,25</a>].</p><p></p><p class="headingAnchor" id="H2661113167"><span class="h3">Electromyography and nerve conduction study</span><span class="headingEndMark"> — </span>EMG and nerve conduction studies should be performed in patients with SSc and suspected myopathy. Nerve conduction studies should be normal, with EMG changes of early recruitment and small-amplitude and short-duration motor unit potentials supporting a diagnosis of myopathy. Evidence of increased membrane irritability (ie, increased insertional activity, fibrillations, positive sharp waves) on EMG suggests an inflammatory myopathy [<a href="#rid6">6,26</a>]. EMG can also be helpful to identify the optimal (ie, most affected) muscle group for biopsy.</p><p class="headingAnchor" id="H4145062394"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) of the weak muscle group is often used in conjunction with EMG to help diagnose the etiology of muscle weakness in a patient with SSc. MRI can also be used to identify the area of most intense muscle edema for biopsy. (See  <a class="medical medical_review" href="/z/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Skeletal muscle imaging'</a>.)</p><p>The most commonly reported finding on MRI in patients with SSc-associated myopathy is muscle edema [<a href="#rid6">6,26</a>]. Intramuscular edema and fascial edema have been reported to be more common in those with an SSc-associated myopathy, especially in those patients who have fewer inflammatory changes on muscle biopsy [<a href="#rid27">27</a>]. Advanced, quantitative imaging techniques such as T2 mapping have also been reported to be helpful in detecting muscle disease in SSc [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H1345901022"><span class="h3">Muscle biopsy</span><span class="headingEndMark"> — </span>A muscle biopsy is typically not required to make the diagnosis of myopathy. It may be helpful if the clinical picture is unclear or to help guide therapy. (See  <a class="medical medical_review" href="/z/d/html/5155.html" rel="external">"Approach to the patient with muscle weakness"</a> and <a class="local">'Management'</a> below.)</p><p>In addition to being helpful diagnostically, the histopathologic features can also have management and prognostic implications  (<a class="graphic graphic_figure graphicRef119673" href="/z/d/graphic/119673.html" rel="external">figure 1</a>). Muscle biopsy is typically performed by a surgeon or a neuromuscular disease specialist. If the overlying skin is very thickened and healing is thought to be poor, the risks and benefits of the biopsy should be carefully weighed. The selection of muscle to biopsy and other aspects of technique are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Muscle biopsy'</a>.)</p><p>Muscle histopathology in SSc-associated muscle disease is heterogeneous [<a href="#rid5">5,6,26,29,30</a>]. In one study of 35 patients with SSc-associated myopathy, 63 percent of biopsies displayed inflammation, atrophy, and necrosis, while 24 percent demonstrated endomysial and perimysial fibrosis [<a href="#rid6">6</a>]. In another series of 42 patients with SSc and muscle weakness, the major histopathologic categories included nonspecific myositis (36 percent), necrotizing myopathy (21 percent), dermatomyositis (7 percent), acute denervation (7 percent), fibrosis only (7 percent), and polymyositis (5 percent) [<a href="#rid26">26</a>]. In this study, the presence of fibrosis on biopsy was strongly associated with anti-PM-Scl antibodies. Also, nearly half of the 42 patients had histologic evidence of acute motor denervation (acute neurogenic atrophy), which had not been previously reported.<em> </em>In contrast to these two studies, another prospective study of 35 patients with SSc-associated myopathy found that muscle fibrosis, in particular, multifocal endomysial fibrosis without necrosis or regeneration, along with microangiopathy was the predominant histologic finding in more than 80 percent of patients [<a href="#rid31">31</a>].</p><p>Our observations suggest that fibrosing myopathy, the subset of patients with fibrosis predominance, may be a distinct subset in SSc-associated myopathy, which appears to be associated with a worse prognosis. In a study of 37 weak SSc patients, eight patients had fibrosing myopathy and 29 had inflammatory myopathy on biopsy. Compared with patients with inflammatory myopathy on biopsy, patients with fibrosing myopathy were more likely to have the diffuse cutaneous SSc subtype, lower mean CK levels, more prevalent nonirritable myopathy on EMG, and higher mortality (usually cardiac related) when compared with patients with an inflammatory myopathy [<a href="#rid20">20</a>].</p><p>On electron microscopy, a specific morphologic pattern termed minimal myositis with capillary pathology may be characteristic of patients with SSc-associated myopathy [<a href="#rid32">32</a>]. In a study including 18 patients with SSc and muscle weakness who had muscle biopsies, 12 of 18 (67 percent) biopsies had this finding on large-scale electron microscopy that demonstrated characteristic capillary morphology with basement membrane thickening and reduplications, endothelial activation, and pericyte proliferation.</p><p class="headingAnchor" id="H1044564472"><span class="h2">Diagnosis and differential diagnosis</span><span class="headingEndMark"> — </span>There are no formal diagnostic criteria for SSc-associated myopathy. A presumptive diagnosis is made in a patient with SSc who has proximal muscle weakness along with objective evidence of myopathy on EMG, MRI, or (ideally) muscle biopsy. While disuse, joint contractures, and malnutrition can cause muscle weakness, in these cases the aforementioned studies typically will not show significant muscle involvement. The differential diagnosis of myopathy in SSc should also include workup for thyroid disease.</p><p>As noted, findings on the muscle biopsy allow identification of patients with features that suggest inflammation (dermatomyositis, polymyositis, nonspecific inflammation) versus those with predominant fibrosis (see <a class="local">'Muscle biopsy'</a> above). These features may help direct appropriate therapy.</p><p class="headingAnchor" id="H1703746987"><span class="h2">Management</span><span class="headingEndMark"> — </span>The management of SSc-associated myopathy will largely depend on the presence of inflammation as evidenced by muscle MRI or, ideally, muscle biopsy. If there is a significant burden of muscle inflammation or necrosis on muscle biopsy, the first step in management is typically immunosuppression. It is less clear whether patients with fibrosing myopathy on muscle biopsy will respond to immunosuppressive therapy. Regardless of the etiology of the muscle weakness, all patients with SSc and muscle involvement should be involved in physical exercise.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression</strong> – Due to the limited data regarding the management of SSc-associated myopathy, the approach to therapy is largely based on clinical experience, observational data, and extrapolation from trials of immunosuppressive agents used in patients with dermatomyositis and polymyositis. For patients with SSc-associated myopathy and histologic evidence of inflammation or necrosis on muscle biopsy, we suggest initiating treatment with a glucocorticoid-sparing agent alone. The authors prefer <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> because it is also used to treat SSc-associated interstitial lung disease; however, the specific choice of treatment is made in the context of the patient's other disease manifestations. If the response is inadequate, low-dose glucocorticoids (typically less than 10 to 20 mg daily of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent) can be used in combination. Some SSc patients are at high risk for developing scleroderma renal crisis, and glucocorticoids are recognized as a risk factor. Accordingly, only cautious use of low-dose glucocorticoids is advised in patients with SSc, and treated patients should be closely monitored for new onset of hypertension. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Mycophenolate mofetil'</a> and  <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent1">Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) is a reasonable alternative therapy for patients who do not respond to <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>. A retrospective study of 52 patients with SSc-associated myopathy revealed that in those who received IVIG, there was a greater decrease of glucocorticoids at three months, and lower glucocorticoid dose at one year after treatment [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Limited data suggest that histologic muscle inflammation and necrosis is associated with a more favorable outcome and a better response to glucocorticoids [<a href="#rid6">6</a>]. The appropriate treatment of fibrosing myopathy in SSc is uncertain [<a href="#rid20">20</a>]. In our experience, early treatment with <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> may lead to clinical improvement in some patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise</strong> – All patients with SSc and muscle involvement should be involved in physical exercise. This recommendation is based upon studies that have demonstrated that exercise improves function and strength in combination with medical treatment in patients with an idiopathic inflammatory myopathy. There are multiple studies demonstrating the safety of exercise even in recent-onset polymyositis/dermatomyositis [<a href="#rid34">34-37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults", section on 'Exercise'</a>.)</p><p></p><p class="bulletIndent1">Given that concomitant sarcopenia is also prevalent in up to 22.5 percent of SSc patients and is associated with functional disability [<a href="#rid38">38</a>], a modified exercise program or physical therapy is advised for patients in conjunction with the medical treatment of SSc-associated myopathy. An eight-week exercise study in patients with SSc showed benefit in muscle endurance and aerobic capacity [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H3792071802"><span class="h1">NEUROPATHY</span></p><p class="headingAnchor" id="H1121959398"><span class="h2">Poly- and mononeuropathies</span><span class="headingEndMark"> — </span>Neuropathy is a rare (1 to 6 percent) complication of systemic sclerosis (SSc; scleroderma) [<a href="#rid39">39,40</a>]. Peripheral neuropathy is much less common than myopathy in SSc. In one electrodiagnostic study of neuropathy in SSc, 60 patients were assessed for a length-dependent peripheral neuropathy; while 28 percent had evidence of a peripheral neuropathy, a potential etiology other than SSc, such as diabetes, was found in 82 percent [<a href="#rid41">41</a>].</p><p>A variety of neuropathy syndromes have been reported in patients with SSc, including [<a href="#rid39">39,42-45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Trigeminal sensory neuropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Sensorimotor peripheral neuropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Carpal tunnel syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple mononeuropathy (also called mononeuritis multiplex)</p><p class="bulletIndent1"><span class="glyph">●</span>Lumbosacral radiculopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Small-fiber neuropathy</p><p></p><p>Patients who report neuropathic symptoms such as burning, tingling, or numbness should undergo a thorough neurologic examination, which may include neurodiagnostic studies as well as an evaluation for a cause other than SSc. Symptoms should be clearly distinguished from Raynaud phenomenon (RP) since similar symptoms can be induced on exposure to cold or stress in SSc patients with RP. The evaluation and treatment of patients with polyneuropathy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy"</a>.)</p><p class="headingAnchor" id="H3760858966"><span class="h2">Autonomic neuropathy</span><span class="headingEndMark"> — </span>Autonomic nervous systemic dysfunction has been observed in SSc and is thought to play a role in altered vascular tone, esophageal contractility, gastrointestinal motility [<a href="#rid46">46-49</a>], and cardiac rhythm abnormalities [<a href="#rid50">50,51</a>] (see  <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">"Gastrointestinal manifestations of systemic sclerosis (scleroderma)"</a>). Autonomic dysfunction also possibly contributes to impotence, which occurs frequently in SSc patients [<a href="#rid52">52-55</a>].</p><p>Laboratory evidence of sympathetic and parasympathetic dysfunction of cardiovascular reflexes is relatively common; however, this is rarely clinically significant [<a href="#rid52">52,56-59</a>]. In addition, an abnormal or absent sympathetic skin response has been demonstrated [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H548656033"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myopathy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Terminology</strong> – There are no formal definitions or a universally accepted classification schema of SSc-associated myopathy. Descriptions of SSc-associated muscle involvement have ranged from muscle weakness and abnormal muscle enzymes to stricter definitions that include abnormal electromyography (EMG) or biopsy-based evidence of inflammation, necrosis, or fibrosis in skeletal muscle. (See <a class="local">'Terminology and epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epidemiology</strong> – Myopathy in systemic sclerosis (SSc; scleroderma) is increasingly recognized as a major contributor to the morbidity and mortality of the disease. Other neurologic abnormalities in SSc that are less common include central, peripheral, and autonomic neuropathies. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – SSc-associated myopathy is suspected in patients with SSc who present with symmetric proximal muscle weakness, with or without elevated muscle enzymes. In cases of suspected overlap myositis with SSc, the most prevalent autoantibodies include anti-PM-Scl, anti-U3-RNP, and anti-Ku antibodies. (See <a class="local">'Physical examination'</a> above and <a class="local">'Clinical features'</a> above and <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent2">EMG and nerve conduction studies should be performed in patients with SSc and suspected myopathy. MRI of the weak muscle group is often used in conjunction with EMG to support the diagnosis and identify the area of most intense muscle edema for biopsy. (See <a class="local">'Electromyography and nerve conduction study'</a> above and <a class="local">'Magnetic resonance imaging'</a> above and <a class="local">'Muscle biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – A presumptive diagnosis of SSc-associated myopathy is made in a patient with SSc who has proximal muscle weakness along objective evidence of myopathy on EMG, MRI, or (ideally) muscle biopsy. Histologic patterns are used to identify different subsets of myopathy, which may also have management and prognostic implications. These patterns include dermatomyositis, polymyositis, fibrosing myopathy, immune-mediated necrotizing myopathy, and nonspecific myositis, as well as neurogenic causes of myopathy  (<a class="graphic graphic_figure graphicRef119673" href="/z/d/graphic/119673.html" rel="external">figure 1</a>). (See <a class="local">'Diagnosis and differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – The management of SSc-associated myopathy will largely depend on the presence of inflammation as evidenced by muscle MRI or muscle biopsy. For patients with SSc-associated myopathy and histologic evidence of inflammation or necrosis on muscle biopsy, we suggest initiating treatment with a glucocorticoid-sparing agent alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The authors prefer <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> because it is also used to treat SSc-associated interstitial lung disease; however, the specific choice of treatment is made in the context of the patient's other disease manifestations. If response is inadequate, low-dose glucocorticoids (typically less than 10 to 20 mg daily of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent) can be used in combination. SSc patients are at high risk for developing scleroderma renal crisis, and glucocorticoids are recognized as a risk factor. Accordingly, only cautious use of low-dose glucocorticoids is advised in patients with SSc, and treated patients should be closely monitored for new onset of hypertension. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2">Regardless of the etiology of the muscle weakness, all patients with SSc and muscle involvement should be involved in physical exercise. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Poly- and mononeuropathies</strong> – Peripheral neuropathy is much less common than myopathy in SSc. A variety of neuropathy syndromes have been reported in patients with SSc, including trigeminal sensory neuropathy, sensorimotor peripheral neuropathy, carpal tunnel syndrome, multiple mononeuropathy (also called mononeuritis multiplex), lumbosacral radiculopathy, and small-fiber neuropathy. (See <a class="local">'Poly- and mononeuropathies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autonomic neuropathy</strong> – Autonomic nervous system dysfunction has been observed in SSc and is thought to play a role in altered vascular tone, esophageal contractility, gastrointestinal motility, and cardiac rhythm abnormalities. (See <a class="local">'Autonomic neuropathy'</a> above.)</p><p></p><p class="headingAnchor" id="H4174197787"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter H Schur, MD, and Monica L Piecyk, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mimori T. Scleroderma-polymyositis overlap syndrome. Clinical and serologic aspects. Int J Dermatol 1987; 26:419.</a></li><li><a class="nounderline abstract_t">Ringel RA, Brick JE, Brick JF, et al. Muscle involvement in the scleroderma syndromes. Arch Intern Med 1990; 150:2550.</a></li><li><a class="nounderline abstract_t">Ranque B, Authier FJ, Berezne A, et al. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 2007; 1108:268.</a></li><li class="breakAll">Mammen AL. Skeletal muscle involvement. In: Scleroderma: From Pathogenesis to Comprehensive Management, Varga J, Denton CP, Wigley FM (Eds), Springer, New York City 2011. p.525.</li><li><a class="nounderline abstract_t">Medsger TA Jr, Rodnan GP, Moossy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968; 11:554.</a></li><li><a class="nounderline abstract_t">Ranque B, Authier FJ, Le-Guern V, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009; 68:1474.</a></li><li><a class="nounderline abstract_t">Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84:231.</a></li><li><a class="nounderline abstract_t">Aguila LA, Lopes MR, Pretti FZ, et al. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin Rheumatol 2014; 33:1093.</a></li><li><a class="nounderline abstract_t">Jung M, Bonner A, Hudson M, et al. Myopathy is a poor prognostic feature in systemic sclerosis: Results from the Canadian Scleroderma Research Group (CSRG) cohort. Scand J Rheumatol 2014; 43:217.</a></li><li><a class="nounderline abstract_t">Paik JJ, Wigley FM, Mejia AF, Hummers LK. Independent association of severity of muscle weakness with disability as measured by the Health Assessment Questionnaire Disability Index in Scleroderma. Arthritis Care Res (Hoboken) 2016; 68:1695.</a></li><li><a class="nounderline abstract_t">Zhou M, Jiang L, Nie L, et al. Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study. Medicine (Baltimore) 2020; 99:e21734.</a></li><li><a class="nounderline abstract_t">Gao AF, Saleh PA, Kassardjian CD, et al. Brachio-cervical inflammatory myopathy with associated scleroderma phenotype and lupus serology. Neurol Neuroimmunol Neuroinflamm 2018; 5:e410.</a></li><li><a class="nounderline abstract_t">Lucchini M, Bortolani S, Monforte M, et al. Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy. Neurol Neuroimmunol Neuroinflamm 2021; 8.</a></li><li><a class="nounderline abstract_t">Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66:754.</a></li><li><a class="nounderline abstract_t">Meyer OC, Fertig N, Lucas M, et al. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34:104.</a></li><li><a class="nounderline abstract_t">Koschik RW 2nd, Fertig N, Lucas MR, et al. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 2012; 30:S12.</a></li><li><a class="nounderline abstract_t">Guillen-Del Castillo A, Pilar Simeón-Aznar C, Fonollosa-Pla V, et al. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Semin Arthritis Rheum 2014; 44:331.</a></li><li><a class="nounderline abstract_t">De Lorenzo R, Pinal-Fernandez I, Huang W, et al. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology 2018; 90:e2068.</a></li><li><a class="nounderline abstract_t">Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112.</a></li><li><a class="nounderline abstract_t">Paik JJ, Wigley FM, Shah AA, et al. Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality. Arthritis Care Res (Hoboken) 2017; 69:1764.</a></li><li><a class="nounderline abstract_t">Sacks DG, Okano Y, Steen VD, et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody. J Rheumatol 1996; 23:639.</a></li><li><a class="nounderline abstract_t">Rigolet A, Musset L, Dubourg O, et al. Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease. Medicine (Baltimore) 2012; 91:95.</a></li><li><a class="nounderline abstract_t">Hoa S, Hudson M, Troyanov Y, et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore) 2016; 95:e4713.</a></li><li><a class="nounderline abstract_t">Landon-Cardinal O, Baril-Dionne A, Hoa S, et al. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open 2020; 6.</a></li><li><a class="nounderline abstract_t">Kaji K, Fertig N, Medsger TA Jr, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) 2014; 66:575.</a></li><li><a class="nounderline abstract_t">Paik JJ, Wigley FM, Lloyd TE, et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken) 2015; 67:1416.</a></li><li><a class="nounderline abstract_t">Ahlawat S, Paik J, Del Grande F, et al. Distinct MR features in scleroderma associated myopathy. Radiol Med 2021; 126:707.</a></li><li><a class="nounderline abstract_t">Ross L, Lindqvist A, Costello B, et al. Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis. Arthritis Res Ther 2022; 24:84.</a></li><li><a class="nounderline abstract_t">Bhansing KJ, Lammens M, Knaapen HK, et al. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Res Ther 2014; 16:R111.</a></li><li><a class="nounderline abstract_t">Matas-García A, Guillén-Del-Castillo A, Kisluk B, et al. Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort. Rheumatology (Oxford) 2023; 62:SI82.</a></li><li><a class="nounderline abstract_t">Corallo C, Cutolo M, Volpi N, et al. Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation. Ther Adv Musculoskelet Dis 2017; 9:3.</a></li><li><a class="nounderline abstract_t">Siegert E, Uruha A, Goebel HH, et al. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol 2021; 141:917.</a></li><li><a class="nounderline abstract_t">Chaigne B, Rodeia S, Benmostefa N, et al. Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. Autoimmun Rev 2020; 19:102431.</a></li><li><a class="nounderline abstract_t">Varjú C, Pethö E, Kutas R, Czirják L. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003; 17:83.</a></li><li><a class="nounderline abstract_t">Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol 1993; 20:1340.</a></li><li><a class="nounderline abstract_t">Alexanderson H, Stenström CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29:295.</a></li><li><a class="nounderline abstract_t">Alexanderson H, Bergegård J, Björnådal L, Nordin A. Intensive aerobic and muscle endurance exercise in patients with systemic sclerosis: a pilot study. BMC Res Notes 2014; 7:86.</a></li><li><a class="nounderline abstract_t">Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. Nutrition 2018; 55-56:51.</a></li><li><a class="nounderline abstract_t">Lee P, Bruni J, Sukenik S. Neurological manifestations in systemic sclerosis (scleroderma). J Rheumatol 1984; 11:480.</a></li><li><a class="nounderline abstract_t">Dyck PJ, Hunder GG, Dyck PJ. A case-control and nerve biopsy study of CREST multiple mononeuropathy. Neurology 1997; 49:1641.</a></li><li><a class="nounderline abstract_t">Paik JJ, Mammen AL, Wigley FM, et al. Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma. Arthritis Care Res (Hoboken) 2016; 68:1150.</a></li><li><a class="nounderline abstract_t">Teasdall RD, Frayha RA, Shulman LE. Cranial nerve involvement in systemic sclerosis (scleroderma): A report of 10 cases. Medicine (Baltimore) 1980; 59:149.</a></li><li><a class="nounderline abstract_t">Farrell DA, Medsger TA Jr. Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 1982; 73:57.</a></li><li><a class="nounderline abstract_t">Beighton P, Gumpel JM, Cornes NG. Prodromal trigeminal sensory neuropathy in progressive systemic sclerosis. Ann Rheum Dis 1968; 27:367.</a></li><li><a class="nounderline abstract_t">Provitera V, Nolano M, Pappone N, et al. Distal degeneration of sensory and autonomic cutaneous nerve fibres in systemic sclerosis. Ann Rheum Dis 2005; 64:1524.</a></li><li><a class="nounderline abstract_t">Cerinic MM, Generini S, Pignone A, Casale R. The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. Rheum Dis Clin North Am 1996; 22:879.</a></li><li><a class="nounderline abstract_t">Akesson A, Gustafson T, Wollheim F, Brismar J. Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheumatol 1987; 16:291.</a></li><li><a class="nounderline abstract_t">Greydanus MP, Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989; 96:110.</a></li><li><a class="nounderline abstract_t">Lock G, Straub RH, Zeuner M, et al. Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J Rheumatol 1998; 25:1330.</a></li><li><a class="nounderline abstract_t">Bertinotti L, Bracci S, Nacci F, et al. The autonomic nervous system in systemic sclerosis. A review. Clin Rheumatol 2004; 23:1.</a></li><li><a class="nounderline abstract_t">Amaral TN, Peres FA, Lapa AT, et al. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 2013; 43:335.</a></li><li class="breakAll">Rosenbaum RB, Campbell SM, Rosenbaum JT. Clinical Neurology of Rheumatic Diseases, Butterworth-Heinemann, Boston 1996.</li><li><a class="nounderline abstract_t">Klein LE, Posner MS. Progressive systemic sclerosis and impotence. Ann Intern Med 1981; 95:658.</a></li><li><a class="nounderline abstract_t">Lally EV, Jimenez SA. Impotence in progressively systemic sclerosis. Ann Intern Med 1981; 95:150.</a></li><li><a class="nounderline abstract_t">Nowlin NS, Brick JE, Weaver DJ, et al. Impotence in scleroderma. Ann Intern Med 1986; 104:794.</a></li><li><a class="nounderline abstract_t">Ferri C, Emdin M, Giuggioli D, et al. Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol 1997; 36:669.</a></li><li><a class="nounderline abstract_t">Klimiuk PS, Taylor L, Baker RD, Jayson MI. Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 1988; 47:542.</a></li><li><a class="nounderline abstract_t">Sonnex C, Paice E, White AG. Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients. Ann Rheum Dis 1986; 45:957.</a></li><li><a class="nounderline abstract_t">Straub RH, Zeuner M, Lock G, et al. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol 1996; 23:87.</a></li><li><a class="nounderline abstract_t">Schady W, Sheard A, Hassell A, et al. Peripheral nerve dysfunction in scleroderma. Q J Med 1991; 80:661.</a></li><li><a class="nounderline abstract_t">Raszewa M, Hausmanowa-Petrusewicz I, Błaszczyk M, Jabłońska S. Sympathetic skin response in scleroderma. Electromyogr Clin Neurophysiol 1991; 31:467.</a></li></ol></div><div id="topicVersionRevision">Topic 7550 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3308722" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Scleroderma-polymyositis overlap syndrome. Clinical and serologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2244771" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Muscle involvement in the scleroderma syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899625" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systemic sclerosis-associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899625" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Systemic sclerosis-associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5676926" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Skeletal muscle involvement in progressive systemic sclerosis (scleroderma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054827" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A descriptive and prognostic study of systemic sclerosis-associated myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010208" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989017" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24650305" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myopathy is a poor prognostic feature in systemic sclerosis: Results from the Canadian Scleroderma Research Group (CSRG) cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26881982" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Independent association of severity of muscle weakness with disability as measured by the Health Assessment Questionnaire Disability Index in Scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32872058" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114565" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Brachio-cervical inflammatory myopathy with associated scleroderma phenotype and lupus serology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011678" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17234652" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17117486" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261302" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anti-PM-Scl antibody in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110305" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728522" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333934" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anti-U3 RNP autoantibodies in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28544788" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730118" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22391471" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27583908" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32892170" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24023044" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25989455" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33394365" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Distinct MR features in scleroderma associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35410246" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24886750" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35713496" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28101144" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864496" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31734403" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12617382" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8230016" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Resistive exercise in the rehabilitation of polymyositis/dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11093595" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507585" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intensive aerobic and muscle endurance exercise in patients with systemic sclerosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29960157" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6090661" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neurological manifestations in systemic sclerosis (scleroderma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409360" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A case-control and nerve biopsy study of CREST multiple mononeuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663579" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6244477" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cranial nerve involvement in systemic sclerosis (scleroderma): A report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091174" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Trigeminal neuropathy in progressive systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4299070" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prodromal trigeminal sensory neuropathy in progressive systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162911" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Distal degeneration of sensory and autonomic cutaneous nerve fibres in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923601" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3629208" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2909417" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9676765" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14749972" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The autonomic nervous system in systemic sclerosis. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827688" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neurologic involvement in scleroderma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827688" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Neurologic involvement in scleroderma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7294569" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Progressive systemic sclerosis and impotence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6789736" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impotence in progressively systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3706932" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Impotence in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236677" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3401050" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Autonomic neuropathy in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3789830" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838514" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661432" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Peripheral nerve dysfunction in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1797542" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sympathetic skin response in scleroderma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
